Research library / Omega-3

AA Multiple randomized trials or meta-analyses, consistent results. How we grade →Meta-analysis of RCTs · 10 RCTs, 77,917 people

Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals

T Aung, J Halsey, D Kromhout, H Gerstein, R Marchioli, L Tavazzi et al. JAMA Cardiology. 2018.

Published Sources checked 1 sourceEverstack research teamHow we work

Bottom line: Across 10 large trials in high-risk adults, omega-3 supplements did not significantly reduce coronary deaths, heart attacks or major vascular events.

In plain language
This meta-analysis pooled 10 large randomized trials, each with at least 500 participants and at least 1 year of treatment, for a total of 77,917 high-risk people with a mean age of 64 who were followed for a mean of 4.4 years. Omega-3 supplements, with EPA doses from 226 to 1,800 mg a day, had no significant link to coronary heart disease death (rate ratio 0.93), nonfatal heart attack (0.97) or major vascular events (0.97). Results were the same in every subgroup, including people with prior coronary heart disease or diabetes and people taking statins.
Limits
It predates the REDUCE-IT, STRENGTH and VITAL results, and most trials used doses of 1 g or less. The analysis used study-level data, not individual patient data.
Which of our grades it feeds
Source
doi.org/10.1001/jamacardio.2017.5205 · PubMed 29387889 · Free full text

Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack. Reviewed . We sell some of what we grade.